Adiyaman Universitesi Egitim ve Arastirma Hastanesi - Cardiology,Adıyaman, Centry - Turquia.
Adiyaman Universitesi Egitim ve Arastirma Hastanesi - Infectious Disease,Adıyaman, Centry - Turquia.
Arq Bras Cardiol. 2020 Jun 1;114(5):817-822. doi: 10.36660/abc.20200273.
Coronavirus disease 2019 (COVID-19) is a global pandemic affecting the world, seen in more than 1,300,000 patients. COVID-19 acts through the angiotensin-converting enzyme 2 (ACE2) receptor. Cardiovascular comorbidities are more common with COVID-19, and nearly 10% of cases develop myocarditis (22% of critical patients). Further research is needed to continue or discontinue ACE inhibitors and angiotensin receptor blockers, which are essential in hypertension and heart failure in COVID-19. Intensive research is promising for the treatment and prevention of COVID-19.
2019 年冠状病毒病（COVID-19）是一种影响全球的全球大流行疾病，已在超过 130 万患者中出现。COVID-19 通过血管紧张素转换酶 2（ACE2）受体起作用。心血管合并症在 COVID-19 中更为常见，近 10%的病例发生心肌炎（重症患者的 22%）。需要进一步研究是否继续或停止使用 ACE 抑制剂和血管紧张素受体阻滞剂，因为它们在 COVID-19 中的高血压和心力衰竭中是必不可少的。针对 COVID-19 的治疗和预防的深入研究很有希望。
